Virtu Financial LLC Sells 22,928 Shares of Altimmune, Inc. (NASDAQ:ALT)

Virtu Financial LLC cut its stake in Altimmune, Inc. (NASDAQ:ALT) by 20.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,831 shares of the company’s stock after selling 22,928 shares during the quarter. Virtu Financial LLC’s holdings in Altimmune were worth $626,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Larson Financial Group LLC purchased a new stake in Altimmune during the third quarter valued at $31,000. SBI Securities Co. Ltd. bought a new stake in shares of Altimmune during the 4th quarter valued at about $45,000. Cullen Frost Bankers Inc. bought a new stake in shares of Altimmune during the 4th quarter valued at about $72,000. 180 Wealth Advisors LLC purchased a new stake in shares of Altimmune during the 4th quarter valued at about $78,000. Finally, Raymond James Financial Inc. bought a new position in shares of Altimmune in the 4th quarter worth approximately $88,000. 78.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALT. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Altimmune Price Performance

Shares of NASDAQ ALT opened at $5.89 on Wednesday. The stock has a market cap of $453.61 million, a PE ratio of -3.80 and a beta of 0.87. Altimmune, Inc. has a 1 year low of $5.14 and a 1 year high of $11.16. The firm has a fifty day moving average price of $6.31 and a 200-day moving average price of $7.08.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Insider Transactions at Altimmune

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.10% of the company’s stock.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.